Finally, the combination of cytotoxic chemotherapies and ICIs may represent an option for PPC cases without any druggable mutations when they harbor a sarcomatoid component that expresses high levels of PD-L1. This evidence concerns the gene CD274 and primary peritoneal carcinoma.